The Öresund Cardiovascular Research Collaboration, The Clinic for Heart Failure and Valvular Disease, Skåne University Hospital, Lund, Sweden.
Acta Physiol (Oxf). 2012 Aug;205(4):507-19. doi: 10.1111/j.1748-1716.2012.02437.x. Epub 2012 May 4.
Hypoxic pulmonary vasoconstriction (HPV) causes pulmonary hypertension that may lead to right heart failure. We hypothesized that the COX-2 inhibitor nimesulide and the thromboxane A(2) receptor antagonist daltroban would attenuate HPV.
Haemodynamic measurements and blood sampling were performed in 18 anaesthetized, mechanically ventilated pigs, with mean ± SEM weights of 31.3 ± 0.6 kg, in normoxia (F(i)O(2)0.21) and hypoxia (F(i)O(2)0.10), before and 5, 15 and 45 min after initiation of right atrial infusion of nimesulide (n = 6) or daltroban (n = 6), respectively, and in six control pigs.
Compared with normoxia, hypoxia (n = 18) increased mean pulmonary artery pressure by 15.8 ± 0.8 mmHg (P < 0.001), pulmonary vascular resistance (PVR) by 2.7 ± 0.3 WU (P < 0.05) and mean right atrial pressure by 2.3 ± 0.3 mmHg (P < 0.001). In the control pigs, mean pulmonary artery pressure, PVR and mean right atrial pressure remained stable (P = ns) throughout 45 min hypoxia, compared with hypoxia baseline. Nimesulide decreased mean pulmonary artery pressure by 3.7 ± 1.3 mmHg after 45 min (P < 0.013), as well as PVR by 0.8 ± 0.2 WU (P < 0.05), levelling off after 15 min. Daltroban transiently increased (P < 0.001) mean pulmonary artery pressure and mean right atrial pressure by 7.2 ± 1.2 and 2.7 ± 0.4 mmHg, respectively, but they returned to hypoxia baseline (P = ns) within 5 min. Daltroban then decreased mean pulmonary artery pressure to after 45 min be 4.2 ± 1.6 mmHg lower (P < 0.005) than at hypoxia baseline.
COX-2 inhibition and thromboxane A(2) receptor antagonism attenuate HPV by decreasing mean pulmonary artery pressure by approximately 10-11%, as measured 45 min after initiation of nimesulide or daltroban infusion respectively.
低氧性肺血管收缩(HPV)导致肺动脉高压,进而可能导致右心衰竭。我们假设 COX-2 抑制剂尼美舒利和血栓素 A2 受体拮抗剂 daltroban 可减轻 HPV。
在 18 只麻醉、机械通气的猪中进行血流动力学测量和采血,平均体重为 31.3 ± 0.6kg,在常氧(FiO20.21)和低氧(FiO20.10)下,分别在右心房输注尼美舒利(n = 6)或 daltroban(n = 6)前、5、15 和 45 分钟后,以及在 6 只对照猪中进行。
与常氧相比,低氧(n = 18)使肺动脉平均压升高 15.8 ± 0.8mmHg(P < 0.001),肺血管阻力(PVR)升高 2.7 ± 0.3WU(P < 0.05),平均右心房压升高 2.3 ± 0.3mmHg(P < 0.001)。在对照猪中,与低氧基础值相比,在整个 45 分钟低氧期间,平均肺动脉压、PVR 和平均右心房压保持稳定(P = ns)。尼美舒利在 45 分钟后降低平均肺动脉压 3.7 ± 1.3mmHg(P < 0.013),降低 PVR 0.8 ± 0.2WU(P < 0.05),15 分钟后趋于平稳。Daltroban 短暂地增加(P < 0.001)平均肺动脉压和平均右心房压分别增加 7.2 ± 1.2 和 2.7 ± 0.4mmHg,但在 5 分钟内恢复到低氧基础值(P = ns)。然后,daltroban 在 45 分钟后将平均肺动脉压降低 4.2 ± 1.6mmHg(P < 0.005),低于低氧基础值。
COX-2 抑制和血栓素 A2 受体拮抗通过分别在尼美舒利或 daltroban 输注开始后 45 分钟左右降低平均肺动脉压 10-11%,减轻 HPV。